Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure

被引:65
作者
Buikema, H
Monnink, SHJ
Tio, RA
Crijns, HJGM
de Zeeuw, D
van Gilst, WH
机构
[1] Univ Groningen, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Cardiol, Groningen, Netherlands
关键词
myocardial-infarction; heart failure; N-acetylcysteine; ACE-inhibitor; SH-group; aorta; ACh; A23187; L-NMMA; NO;
D O I
10.1038/sj.bjp.0703498
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We evaluated the role of SH-groups in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. To this end, we compared the vasoprotective effect of chronic treatment with zofenopril (plus SH-group) versus lisinopril (no SH-group), or N-acetylcysteine (only SH-group) in myocardial infarcted (MI) heart failure rats. 2 After 11 weeks of treatment, aortas were obtained and studied as ring preparations for endothelium-dependent and -independent dilatation in continuous presence of indomethacin to avoid interference of vasoactive prostanoids, and the selective presence of the NOS-inhibitor L-NMMA to determine NO-contribution. 3 Total dilatation after receptor-dependent stimulation with acetylcholine (ACh) was attenuated (-49%, P < 0.05) in untreated MI (n = 11), compared to control rats with no-MI (n = 8). This was in part due to impaired NO-contribution in MI (-50%, P < 0.05 versus no-MI). At the same time the capacity for generation of biologically active NO after receptor-independent stimulation with A23187 remained intact. 4 Chronic treatment with n-acetylcysteine (n = 8) selectively restored NO-contribution in total dilatation to ACh. In contrast, both ACE-inhibitors fully normalized total dilatation to ACh, including the part mediated by NO (no significant differences between zofenopril (n = 10) and lisinopril (n = 8)). 5 Zofenopril, but not lisinopril, additionally potentiated the effect of endogenous NO after A23187-induced release from the endothelium (+100%) as well as that of exogenous NO provided by nitroglycerin (+22%) and sodium nitrite (+36%) (for all P < 0.05 versus no-MI). 6 We conclude that ACE-inhibition with a SH-group has a potential advantage in improvement of endothelial dysfunction through increased activity of NO after release from the endothelium into the vessel wall. Furthermore, this is the first study demonstrating the selective normalizing effect of N-actylcysteine on NO-contribution to ACh-induced dilatation in experimental heart failure.
引用
收藏
页码:1999 / 2007
页数:9
相关论文
共 37 条
[1]   Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression -: Role of enhanced vascular superoxide production [J].
Bauersachs, J ;
Bouloumié, A ;
Fraccarollo, D ;
Hu, K ;
Busse, R ;
Ertl, G .
CIRCULATION, 1999, 100 (03) :292-298
[2]  
Buikema H, 1997, J Card Fail, V3, P125, DOI 10.1016/S1071-9164(97)90046-4
[3]  
Buikema H, 1996, EUR HEART J, V17, P787
[4]   Effect of short- and long-term heart failure on small artery morphology and endothelial function in the rat [J].
Buus, NH ;
Kahr, O ;
Mulvany, MJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (01) :34-40
[5]   Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction [J].
deVries, RJM ;
Anthonio, R ;
vanVeldhuisen, DJ ;
Scholtens, E ;
Buikema, H ;
vanGilst, WH .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (05) :683-689
[6]   ENDOTHELIAL FUNCTION IN CONGESTIVE-HEART-FAILURE [J].
DREXLER, H ;
HAYOZ, D ;
MUNZEL, T ;
JUST, H ;
ZELIS, R ;
BRUNNER, HR .
AMERICAN HEART JOURNAL, 1993, 126 (03) :761-764
[7]  
FEELISCH M, 1991, J CARDIOVASC PHARM, V17, P27
[8]   p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats [J].
Fukui, T ;
Ishizaka, N ;
Rajagopalan, S ;
Lauren, JB ;
Capers, Q ;
Taylor, WR ;
Harrison, DG ;
deLeon, H ;
Wilcox, JN ;
Griendling, KK .
CIRCULATION RESEARCH, 1997, 80 (01) :45-51
[9]  
GALEN MP, 1998, J CARDIOVASC PHARM, V32, P101
[10]  
GIVERTZ MM, 1998, LANCET S1, V352, pS135